Abstract
Long-term Efficacy, Safety, and Immunogenicity Data From a Phase III Confirmatory Study Comparing GP2017, a Proposed Biosimilar, With Reference Adalimumab
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have